TRIVECTA
PHARMACEUTICALS
Trivecta Pharmaceuticals is a leading biotechnology pharmaceutical research company, focused on Public Health Emergencies and the development of innovative pharmaceutical products and medical devices and diagnostics. Our robust pipeline of biosimilars help us mitigate through our goals and we are aiming to bring more cost-effective drugs, products and medical devices into the marketplace; to make them more accessible to patients in need and to help reduce the burden and high cost this takes in the hospitals and healthcare systems.
Our well specialized compliance and FDA regulatory affairs team is capable to design anything from clinical trials Phase 1-2-3 from product development until product approval and commercialization. This includes product development, biologics and vaccines, immunotherapy treatments, medical devices, drug development and more.
Trivecta is also designing its parenteral solutions plant which will have a biomanufacturing capacity of 260. 000 litters of bioreactors and parenteral solutions per day. This plant is aiming to break ground in 2025 and have an approximate delivery time of 14-16 1months for completion of the project and will meet all FDA regulatory requirements including cGCP, cGMP, cGLP and QMM standards.
Attached to the plant, Trivecta will also have 3 BSL3 Biosafety mobile labs category 3-4 that will serve independently from the main building and will help us mitigate through public health emergencies. The lab infrastructure maintains the highest standards of quality control and safety require to navigate through a potential pandemic including and maintaining all cGCP cGMP cGLP active and in place.
All BSL3 labs will act independently from the main manufacturing building, air conditionings, air filters, pipelines etc. ensuring quality control and safety vigilance and that mechanisms are in place at all times.
The proposed parenteral solutions Phase 1 plant will be built and assemble in an approximate 100.000 square footage facility and will be complemented with different clean rooms ready to be adapted for other units such as injectables and other manufacturing production capabilities, as well as its own final product storage facilities, raw storage warehousing, internal lab and R&D center.
Trivecta's team looks forward to build a state-of-the-art integrated facility that can have sufficient manufacturing capacity to provide not only our region but also our nation and nation allies during public health emergencies.
At Trivecta, we take pride of being a small, women own, minority business. Among our product pipeline we also have the Medical Devices and Diagnostics unit, the Women Health Unit, Anti-Opioids Unit, Mental Health Unit and Neurosciences Unit.
Trivecta is also proud of working in a variety of different biosimilars including cancer drugs that we are aiming to bring to market and commercialization.
300 SE 2nd Street Suite 600Fort Lauderdale, Florida 33301
Phone 1-5618560842 1-9548319936
publichealth@lsipms.com
Our integrated solutions and cleanrooms infrastructure provide ease of scalability, full integration and fast turnaround across all process applications.
Our manufacture lab and clean rooms will meet the highest standards of safety including cGCP - cGLP -cGMP and QMM standards to ensure quality and safety at all times.
Integrating all manufacturing needs and solutions under one roof while protecting public health and safety.
Our 100k sq. ft facility will include different cleanrooms, labs, R&D lab, storage areas for raw materials and lab mixer areas while maintaining the highest quality control and QMM standards including FDA cGCP - cGMP -cGLP and ISO at all times, while maintaining each air filter separated from each cleanroom.
Ensuring safety in our pipeline of in-house manufacturing products.
Trivecta Biologics takes pride of its robust pipeline of biosimilars in developing process while aiming to reduce drug cost and have easy and faster accessibility to patients in need.
Designing the future of our domestic pharmaceutical manufacturing.
260k liters of bioreactors per day.
62.4 million liters of bioreactors per year.
250m units + per year
Cell Therapy Development Lab
Cell Expansion Safety Clean Rooms
Aseptic Filling Combination Product Lab
